| Name | Dutasteride |
| Description | Dutasteride (GI 198745) is a 5-alpha-reductase inhibitor that inhibits both type-1 and type2 isoforms of the enzyme and is used to treat benign prostatic hyperplasia. |
| In vitro | In healthy male rats, daily treatment with Dutasteride (100mg/kg) resulted in a prostate size that was half the size of that in control rats. |
| In vivo | Dutasteride effectively inhibits Type I 5AR (IC50=6 nM) and Type II 5AR (IC50=7 nM). In LNCaP cells (IC50=1 μM), it suppresses DHT-induced PSA secretion and proliferation, and competes for androgen receptor (AR) binding (IC50=1.5 μM). Additionally, dutasteride reduces cell viability and proliferation in both androgen-responsive (LNCaP) and androgen-nonresponsive (DU145) human prostate cancer (PCa) cell lines. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 6 mg/mL (11.35 mM), Sonication is recommended.
10% DMSO+90% Corn Oil : 2.5 mg/mL (4.73 mM), Sonication is recommeded.
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 44.5 mg/mL (84.2 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | GI-198745 | GI198745 | GG-745 | GG745 | Dutasteride | Apoptosis | 5α-reductase | 5-α reductase | 5 alpha Reductase |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Orally Active Compound Library | Bitter Compound library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
United States
